



Healthcare
Improvement
Scotland

SMC
Advice on new
medicines

www.scottishmedicines.org.uk

Statement of advice
SMC2809

elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide film-coated tablet 90 mg / 90 mg / 120 mg / 6 mg (Genvoya®)

Gilead Sciences Ltd

04 April 2025

ADVICE: in the absence of a submission from the holder of the marketing authorisation:

elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya®) is not recommended for use within NHSScotland.

Indication under review: treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in paediatric patients aged from 2 years and with body weight at least 14 kg to less than 25 kg.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result, we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair
Scottish Medicines Consortium

Published 12 May 2025